JP2017101009A5 - - Google Patents

Info

Publication number

JP2017101009A5

JP2017101009A5 JP2015237951A JP2015237951A JP2017101009A5 JP 2017101009 A5 JP2017101009 A5 JP 2017101009A5 JP 2015237951 A JP2015237951 A JP 2015237951A JP 2015237951 A JP2015237951 A JP 2015237951A JP 2017101009 A5 JP2017101009 A5 JP 2017101009A5

Authority

JP

Japan

Prior art keywords

acanthamoeba

plane

peak intensity

intensity ratio

infections

Prior art date

2015-12-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 241000224422 Acanthamoeba Species 0.000 description 5
• 208000015181 infectious disease Diseases 0.000 description 3
• 206010061618 Acanthamoeba infection Diseases 0.000 description 2
• 208000020222 Acanthamoeba infectious disease Diseases 0.000 description 2
• 208000004881 Amebiasis Diseases 0.000 description 2
• 239000003795 chemical substances by application Substances 0.000 description 2
• 230000009036 growth inhibition Effects 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 241000224423 Acanthamoeba castellanii Species 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 101800004361 Lactoferricin-B Proteins 0.000 description 1
• 108010063045 Lactoferrin Proteins 0.000 description 1
• 102000010445 Lactoferrin Human genes 0.000 description 1
• 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
• 208000001388 Opportunistic Infections Diseases 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 239000003814 drug Substances 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 206010014599 encephalitis Diseases 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 206010023332 keratitis Diseases 0.000 description 1
• CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
• CFFMZOZGXDAXHP-HOKBLYKWSA-N lactoferricin Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@H](C(=O)N1)[C@@H](C)O)=O)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CFFMZOZGXDAXHP-HOKBLYKWSA-N 0.000 description 1
• 229940078795 lactoferrin Drugs 0.000 description 1
• 235000021242 lactoferrin Nutrition 0.000 description 1